About SINOMAB BIO-B Company

China Antibody Pharmaceutical Co., Ltd. (“China Antibody” or the “Company”, stock code: 3681.HK) focuses on the research, development, manufacture and commercialization of immune disease therapies. The company focuses on scientific research and development. Its flagship product, SM03, is the world's first potential anti-CD22 monoclonal antibody for the treatment of rheumatoid arthritis. It has entered phase III clinical trials for rheumatoid arthritis in China, and has been included in the country's 135 major new drug development projects. In addition, there are a number of first-in-target (First-in-Target) and first-in-class (First-in-class) potential drugs under development, some of which are in the clinical phase. Indications cover diseases such as rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, and asthma, which have significant unmet clinical needs.